SRRK

Scholar Rock Holding Corporation (NASDAQ:SRRK) is a Cambridge, Massachusetts-based biopharmaceutical company founded in 2012 that focuses on discovering and developing medicines targeting protein growth factor signaling pathways. The company went public in May 2018 and has emerged as a leader in developing highly selective inhibitors of latent growth factor activation, particularly targeting myostatin and transforming growth factor beta (TGF-β) pathways. Scholar Rock's lead drug candidate, apitegromab, recently completed successful Phase 3 clinical trials for treating spinal muscular atrophy and is currently under regulatory review by the FDA, with potential approval expected in September 2025.